活動資訊

TRPMA去年12月與Ergomed共同舉辦「Harnessing the Potential of the US and Europe in Multi-Regional Clinical Trials」論壇，迴響熱烈！今年Ergomed執行董事長Miroslav Reljanovic及CRO總裁David Selkirk親自來台，與TRPMA再度合作，於3月19日下午舉辦「Strategies for Partnering with KOLs and Sites in the US and Europe to Enhance Performance in Clinical Trials」論壇。

Ergomed 將由Strategic Solutions and Patient Centricity策略解決方案與病人中心資深副總裁Juliet Moritz分享新藥公司與美國、歐洲KOLs、CRCs合作的成功策略。Panel Discussion 將由TRPMA常務理事葉志鴻、TiBIA理事長閻雲教授與Ergomed 高層對談，從全球觀點討論新藥公司應如何給予KOLs及臨床試驗中心支持，以提升臨床試驗的品質及成效。

本論壇將涵蓋新醫藥公司與KOLs及臨床試驗中心，進行臨床試驗各階段的合作策略，包括：試驗起始時如何選擇及邀請PI與選擇臨床試驗中心、如何建立彼此長期的合作夥伴關係、如何解決臨床試驗中心特定的需求與挑戰，以及針對不同治療領域、國家、和臨床試驗計畫書制定因應方案。Ergomed將分享其多年來，於全球60餘國的CRO經驗。

本活動全程免費，交流時段由Ergomed贊助茶點、咖啡及紅酒，歡迎台灣生技新藥公司及各界先進踴躍參加！

主辦單位：台灣研發型生技新藥發展協會 (TRPMA)、Ergomed Group
時間：113年3 月19 日 (星期二) 14:00-17:00
地點：TRPMA會所演講廳 (台北市南港區忠孝東路六段465-1號1樓)
議程：

Ergomed Group https://ergomedgroup.com/

Ergomed is an award-winning full-service clinical development and research company with operations in over 60 countries and 6 continents specializing in oncology, rare and orphan diseases, and complex clinical trials. Founded by former PIs, Ergomed has a deep understanding of site needs and provides unparalleled site support models, ultimately boosting patient recruitment and retention, and overall data quality.

【Speaker BIO】

George Yeh
Standing Director, TRPMA
President, TLC BioSciences

George Yeh is the Standing Director at TRPMA and President of TLC BioSciences. George is responsible for strategic planning of the TLC’s drug programs, business operations, corporate development, product licensing, and management of corporate funding. George was previously Vice President of AsiaWired Group, Inc., a venture advisory company, and Chief Financial Officer of Hermes Biosciences, now a part of Merrimack Pharmaceuticals. George received his Master of Architecture and MBA from the University of Michigan - Ann Arbor and his BA in Architecture from the University of California, Berkeley.

Yun Yen
President, TiBIA

Dr. Yen received a M.D. from Taipei Medical College in 1982 and a Ph.D. in Pathology and Cell Biology from Thomas Jefferson University in 1988. Dr. Yen serves as an Adjunct Professor at Case Western Reserve University and California Institute of Technology, as well as an Emeritus President at Taipei Medical University in Taiwan. Dr. Yen’s prior experience includes service as the Allen and Lee Chao Endowed Chair in Developmental Cancer Therapeutics at the City of Hope Comprehensive Cancer Center from 2008 until 2014, Chair of the City of Hope’s Molecular Pharmacology Department, Interim Chair at the City of Hope Medical Oncology, and Associate Director for Translational Research at the City of Hope Comprehensive Cancer Center from 2005 until 2014. Dr. Yen holds memberships or fellowships in numerous professional organizations, including National Academy of Inventors, Russian Academy of Engineering, and American Association for the Advancement of Science, and has published more than 343 peer-reviewed journal articles.

Dave Selkirk
President, Ergomed CRO

Dave is a seasoned industry executive and President at Ergomed CRO. Dave graduated from the University of Western Ontario with a BSc in Biology, and brings over 3 decades of experience in the Biotech and Pharma Research industry. His experience spans all therapeutic areas and phases of clinical trials, as well as pre-clinical research, central & esoteric labs, post-marketing/market access, along with clinical trial technology. He has a broad international perspective from N. America, Europe, APAC, and LATAM, including a broad list of Sites of excellence and KOLs he has worked with in his career.

Juliet Moritz
Senior Vice President, Strategic Solutions and Patient Centricity, Ergomed

Juliet has over 30 years of global biotech research industry experience across multiple therapeutic areas, spanning Phases I-IV. Juliet brings extensive experience in rare diseases, advanced therapies and complex trials. Her work ensures clinician engagement and patient voices are integral to the drug development process, enhancing outcomes. She has a doctorate in Bioethics, a Masters in Public Health, holds a Professional Certification in Genetics/Genomics and is a Level I certified Professional Patient Advocate in the Life Sciences (PPALS).